Onkologie. 2015:9(6):288-290 [Urol. praxi, 2015; 16(4): 154-156]

Controversies in the hormonal treatment of castration-resistant prostate cancer

Jana Katolická
Onkologicko-chirurgické oddělení FN u sv. Anny, Brno

Abiraterone and enzalutmide also led to an improved overal survival in docetaxel-treated patients with castration-resistant prostate cancer. Both have also been studied in chemotherapy –naive patients. Abiraterone and enzalutamide have less toxicity when compared to chemotherapeutic options. It is now clear that cross resistance is a potential therapeutic issue between hormonal agents.

Keywords: castration-resistant prostate cancer, abiraterone, enzalutamide

Published: December 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Katolická J. Controversies in the hormonal treatment of castration-resistant prostate cancer. Onkologie. 2015;9(6):288-290.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Tannock IF, de Wit R, Berrry WR, et al. Docetaxel plus prednison or mitoxantrone plus prednison for advanced prostate cancer. N Engl J Med. 2004; 351: 1502-1512. Go to original source... Go to PubMed...
    2. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone ad prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351: 1513-1520. Go to original source... Go to PubMed...
    3. de Bonno JS, Logothetis ChJ, et al. Abiraterone and Oncreased Survival in Metastatic Prostate Cancer. N Engl J Med. 2011; 364: 1995-2005. Go to original source... Go to PubMed...
    4. Ryan CJ, Smith MR, De Bono JS, Molina A, Logothetis CJ et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. New Engl J Med 2013; 368: 138-148. Go to original source... Go to PubMed...
    5. Tran C, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-790. Go to original source... Go to PubMed...
    6. Hu R, et al. Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Rev Endocrinol Metab 2010; 5: 753-764. Go to original source... Go to PubMed...
    7. Scher HI, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Eng J Med 2012; 367: 1187-1197. Go to original source... Go to PubMed...
    8. http://investors.medivation.com/releasedtail.cfm?ReleaseID=798880 (accessed November 19,2013).
    9. Sartor O, Gillessen S: Treatment sequencing in metastatic castrate-resistant prostate cancer. Asian Journal of Andrology 2014; 16: 426-431. Go to original source... Go to PubMed...
    10. Mezynski J, Pezaro C, Bianchini D, Zivi A, Sandhu S, et al. Antitumor aktivity of docetaxel following treatment with CYP17A1 inhibitor abiraterone: clinical evidence of cross-resistance? Ann Oncol 2012; 23: 2943-2947. Go to original source... Go to PubMed...
    11. Schrader AJ, Boegemann M, Ohlmann Ch, Schnnoeller TJ, Krabbe LM, et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 2014; 65: 30-36. Go to original source... Go to PubMed...
    12. Bianchini D, Lorenzo D, Roudriguez-Vida A, Omlin A, Pezaro C, et al. Antitumor aktivity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer; a phase 1-2 study. Lancet 2010; 375: 1437-1446. Go to original source... Go to PubMed...
    13. HU R, LU c, Mostaghel EA, et al. Distinct transcriptional programs mediated by the ligand-dependent full-lenght androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 2012; 72: 3457-3462. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.